InsiderSignalSign in
← Insider buys

Noubar Afeyan has bought stock on 2 days since Jun 2019

Director at Moderna, Inc., and 2 other companies

SEC CIK 0001222012 · Filings on SEC.gov ↗

$95.0MBought
$1.7BSold
Mar 2Last buy

Noubar Afeyan's record

3 months after each buy, from the first price a copier could get.

1 buy has 3 months of prices so far. A record shows here at 3.

Companies

Every filing

89 filings since May 2016, newest first

MRNASell

Moderna, Inc.

Director

$434KMay 22
GENBBuy

Generate Biomedicines, Inc.

Director and 10% owner

$75.0M+8.0%Mar 2
MRNASell

Moderna, Inc.

Director

$703KDec 15
MRNASell

Moderna, Inc.

Director

$1.8MAug 2
MRNASell

Moderna, Inc.

Director

$1.8MJul 26
MRNASell

Moderna, Inc.

Director

$1.8MJul 19
MRNASell

Moderna, Inc.

Director

$1.8MJul 12
MRNASell

Moderna, Inc.

Director

$1.9MJun 28
MRNASell

Moderna, Inc.

Director

$2.0MJun 21
MRNASell

Moderna, Inc.

Director

$2.2MJun 14
MRNASell

Moderna, Inc.

Director

$30.1M−2.0%Jun 11
MRNASell

Moderna, Inc.

Director

$2.3MJun 7
MRNASell

Moderna, Inc.

Director

$2.9MMay 31
MRNASell

Moderna, Inc.

Director

$2.4MMay 24
MRNASell

Moderna, Inc.

Director

$1.9MMay 17
MRNASell

Moderna, Inc.

Director

$1.8MMay 10
MRNASell

Moderna, Inc.

Director

$1.7MMay 3
MRNASell

Moderna, Inc.

Director

$1.6MApr 26
MRNASell

Moderna, Inc.

Director

$1.6MApr 19
MRNASell

Moderna, Inc.

Director

$1.6MApr 12
MRNASell

Moderna, Inc.

Director

$1.5MApr 5
MRNASell

Moderna, Inc.

Director

$1.6MMar 29
MRNASell

Moderna, Inc.

Director

$1.5MMar 22
MRNASell

Moderna, Inc.

Director

$1.6MMar 15
MRNASell

Moderna, Inc.

Director

$760KNov 3
MRNASell

Moderna, Inc.

Director

$770KOct 27
MRNASell

Moderna, Inc.

Director

$1.5MOct 13
MRNASell

Moderna, Inc.

Director

$1.5MOct 6
MRNASell

Moderna, Inc.

Director

$990KSep 29
MRNASell

Moderna, Inc.

Director

$1.6MSep 22
MRNASell

Moderna, Inc.

Director

$1.6MSep 15
MRNASell

Moderna, Inc.

Director

$1.6MSep 8
MRNASell

Moderna, Inc.

Director

$1.7MSep 1
MRNASell

Moderna, Inc.

Director

$1.7MAug 25
MRNASell

Moderna, Inc.

Director

$976KAug 18
MRNASell

Moderna, Inc.

Director

$1.7MAug 4
MRNASell

Moderna, Inc.

Director

$1.8MJul 28
MRNASell

Moderna, Inc.

Director

$1.9MJul 21
MRNASell

Moderna, Inc.

Director

$1.9MJul 14
MRNASell

Moderna, Inc.

Director

$1.9MJul 7
MRNASell

Moderna, Inc.

Director

$1.8MJun 30
MRNASell

Moderna, Inc.

Director

$1.8MJun 23
MRNASell

Moderna, Inc.

Director

$1.9MJun 16
MRNASell

Moderna, Inc.

Director

$1.9MJun 9
MRNASell

Moderna, Inc.

Director

$1.9MJun 2
MRNASell

Moderna, Inc.

Director

$1.4MMar 3
MRNASell

Moderna, Inc.

Director

$1.6MFeb 24
MRNASell

Moderna, Inc.

Director

$1.7MFeb 17
MRNASell

Moderna, Inc.

Director

$3.4MFeb 10
MRNASell

Moderna, Inc.

Director

$1.9MJan 27
Older filings
About Noubar Afeyan

Noubar Afeyan is a prominent entrepreneur and venture capitalist who serves as Co-Founder and Chairman of Generate:Biomedicines, as well as Founder and CEO of Flagship Pioneering, a leading life sciences venture capital firm( With a Ph.D. in chemical engineering, Afeyan has built a distinguished career at the intersection of science and entrepreneurship, founding and leading multiple biotech ventures. He holds approximately 57.7% ownership in Generate:Biomedicines, the Somerville, Massachusetts-based company that uses artificial intelligence to revolutionize drug discovery and create new protein-based therapeutics(

As a director and 10% public owner of Generate:Biomedicines, Afeyan has been actively engaged in the company's recent capital activities( In February 2026, Afeyan received a stock option covering 29,561 shares vesting in February 2027, and Flagship Pioneering-affiliated funds under his direction purchased 4.6 million shares of common stock at $16.00 per share( His leadership extends beyond Generate:Biomedicines through Flagship Pioneering, where he directs a portfolio of innovative life sciences companies and maintains significant influence over the firm's strategic investments and operations.

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.